Haemodialysis Research

Leading young researchers describe their current patient-centred research from epidemiological, immunological and psychological perspectives Schedule: 1. 13:30-14:00 Dialysis After Graft Loss - Survival Factors 2. 14:00-14:30 Dialysis After Graft Loss - Immune Injury 3. 14:30-15:00 Patient Related Outcomes with Haemodiafiltration Dialysis After Graft Loss - Survival Factors Kidney transplant failure contributes to a considerable proportion of new dialysis starters. In some centres there are dedicated clinics for patients with failing kidney transplants, however, the specific needs of patients with dialysis after graft loss (DAGL) may be lost in the non-specific clinical review practiced in the general dialysis community. This talk examines the mortality and morbidity risk in patients returning with DAGL. We will discuss the epidemiology of patients returning to dialysis after graft loss to identify areas of concern in management that warrant a more specialised approach. Dialysis After Graft Loss- Immune Harm Advancements in clinical practices and improved management of chronic conditions have resulted in kidney transplant recipients living longer, which has caused a rise in patients returning to dialysis after graft failure and being waitlisted for re-transplantation. Additionally, there has been an increase in the use of deceased donor organs in transplantation. Most patients who return to dialysis after graft failure are taking at least one immunosuppression medication, which can lead to increased morbidity and mortality with prolonged use. However, balancing the risk of withdrawal of these medications with the risk of sensitisation for future transplantation is crucial. Therefore, patient selection and timing of relisting should be approached with an individualised and tailored approach to immunosuppression regimes. New Developments in Patient-Reported Outcomes with Results for Use in Person-Centered Kidney Care The presentation will introduce how a current, structured, science-based patient-reported outcomes questionnaire look like, what its uses are, and how to recognize well-designed questionnaires beyond legacy instruments such as the KDQOL. Examples from recent studies such as the CONVINCE trial on hemodiafiltration will be presented showing new results that demonstrate their benefits in making treatment gaps and improvements visible from the perspective of the patient. There will also be an outlook into new developments of electronic patient-reported outcomes, including computer-adaptive testing using item-response theory that allows for interactive questionnaires that aim to reduce response burden and increase information content.